Indian company Translumina Therapeutics announces the initiation of direct operations in the UAE

Translumina Therapeutics, India's largest domestic player in the coronary stents market, has successfully established their own manufacturing capabilities and developed in-house product lines, which are endorsed by interventional cardiologists worldwide.

The company's drug-eluting stent technologies have been developed through a technological collaboration with the prestigious German Heart Centre, which has led to the development of groundbreaking medical devices, including the world's longest-studied DES, with over 10 years of safety and efficacy data.

"At Translumina, we have a clear ambition to put India on the global map for medical devices and fulfil our national vision of 'Make in India, Make for the world'. Indian engineering & innovation will be at the forefront of the medical devices industry, and the launch of our direct presence in the UAE is a step in that direction," remarked Gurmit Singh Chugh, Co-Founder and Chairman of Translumina Therapeutics.

"We are excited to establish our presence in the UAE, known for its strategic importance and business innovation," added Indranil Mukherjee, Group CEO of Translumina. "This will allow us to better serve the MENA region while strengthening our global presence and making high-quality healthcare more accessible."